How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden Full Text available with Trip Pro

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use (...) ) or second-ever (n = 4347) bDMARD, a biologics-naive cohort treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (n = 46 610), and a general population comparator cohort (n = 107 491).Treatment with tocilizumab, abatacept, rituximab, or TNFi.Outcomes included a first invasive solid or hematologic malignant neoplasm, or skin cancer. Hazard ratios were calculated using Cox-regression, adjusted for age, sex, disease and treatment characteristics, and educational level.We

2017 EvidenceUpdates

2. Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. Full Text available with Trip Pro

Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).To examine the association between hydrochlorothiazide use and the risk for MCC and MAST.Using (...) Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide.The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0

2018 Journal of American Academy of Dermatology

3. Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma)

Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma) Clinical practice guidelines for keratinocyte cancer - Clinical Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Bowel cancer Lung cancer Prostate cancer Skin cancer Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Keratinocyte Cancers Guideline Working Party. Clinical practice guidelines for keratinocyte cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2020 Feb 19]. Available from: . Please also see the following files: This is a wiki-based guideline. A PDF

2020 Cancer Council Australia

4. Squamous cell carcinoma of the skin

Squamous cell carcinoma of the skin Squamous cell carcinoma of the skin - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Squamous cell carcinoma of the skin Last reviewed: February 2019 Last updated: August 2018 Summary Malignant tumour of keratinocytes arising in the epidermis of the skin. Second most common non-melanoma skin cancer worldwide, secondary to basal cell carcinoma. Cumulative ultraviolet exposure, most (...) commonly from the sun, and immunosuppression are major risk factors. Treatments include non-surgical destruction (e.g., using cryotherapy), topical chemotherapy, traditional surgical excision, and Mohs micrographic surgery. Definition Cutaneous squamous cell carcinoma (SCC) is the proliferation of atypical, transformed keratinocytes in the skin with malignant behaviour. It ranges from in situ tumours (also known as Bowen's disease) to invasive tumours and metastatic disease. [Figure caption

2018 BMJ Best Practice

5. Squamous cell carcinoma of the renal pelvis presenting as an integumentary neoplasm of the flank: A case report. Full Text available with Trip Pro

Squamous cell carcinoma of the renal pelvis presenting as an integumentary neoplasm of the flank: A case report. Although chronic pyelonephritis and urolithiasis are established risk factors for squamous cell carcinoma (SCC), only a minority of patients with chronic urolithiasis eventually develop SCC. It is believed that the chronic irritation leads to squamous cell metaplasia that may subsequently develop into SCC. Although studies show that SSC generally spreads locally with associated (...) symptoms of lymphadenopathy, metastasis to the lungs and liver have also been reported. However, cases spreading to the flank have yet to be reported. Therefore, the use of reconstructive techniques for the repair of extensive soft tissue defects in the flank region after extended retroperitoneal resection, is unknown.We report a 54-year-old man who presented with a 1-month history of an enlarged skin mass on the right flank.The patient was subsequently diagnosed with metastatic SCC involving

2019 Medicine

6. Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis. Full Text available with Trip Pro

carcinoma (BCC), squamous cell carcinoma (SCC), actinic keratosis, and malignant melanoma were 92.4%, 92.3%, 73.8%, and 81.0%, respectively. The pooled specificities were 86.9%, 99.5%, 91.5%, and 93.8%, respectively. OCT appears to be useful for the detection of BCC and SCC. It is a valuable diagnostic method when screening for early skin cancers.(2018) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). (...) Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis. Optical coherence tomography (OCT) is an emergent imaging tool used for noninvasive diagnosis of skin diseases. The present meta-analysis was carried out to assess the accuracy of OCT for the diagnosis of skin cancer. We conducted a systematic literature search though EMBASE, Medline, PubMed, the Cochrane Library, and Web of Science database for relevant articles published up to June 6, 2017. The quality

2018 Journal of biomedical optics

7. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Full Text available with Trip Pro

Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Early accurate detection of all skin cancer types is essential to guide appropriate management, reduce morbidity and improve survival. Basal cell carcinoma (BCC) is usually localised to the skin but has potential to infiltrate and damage surrounding tissue, while cutaneous squamous cell carcinoma (cSCC) and melanoma have a much higher potential to metastasise and ultimately lead to death. Exfoliative (...) scrape can never give the same information as a skin biopsy, however, so it is important to better understand in which skin cancer situations it may be helpful.To determine the diagnostic accuracy of exfoliative cytology for detecting basal cell carcinoma (BCC) in adults, and to compare its accuracy with that of standard diagnostic practice (visual inspection with or without dermoscopy). Secondary objectives were: to determine the diagnostic accuracy of exfoliative cytology for detecting cSCC

2018 Cochrane

8. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Comparative Effectiveness Review Number 199 Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Evidence Summary Introduction Skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common malignancies in the United States. 1 BCC and SCC, the 2 most common skin cancers, are collectively referred to as keratinocyte carcinomas. Over 5.4 million of these lesions are diagnosed (...) in square brackets. RoB = risk of bias; BCC = basal cell carcinoma; SCCIS = squamous cell carcinoma in situ; MMS = Mohs micrographic surgery; PDT = photodynamic therapy; RCT = randomized controlled trial; NRCS = nonrandomized comparative study; CI = confidence interval Table E. Summary conclusions for SCCIS lesions and strength of the relevant evidence (continued)References 1. Centers for Disease Control and Prevention Skin Cancer Statistics. 2015. http://www.cdc.gov/cancer/skin/statistics/index. htm. 2

2017 Effective Health Care Program (AHRQ)

9. Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? Full Text available with Trip Pro

Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? Second primary cancers (SPCs) are becoming a common cancer entity, which may interfere with survival in relatively benign first primary cancers. We examined the hypothesis that immune dysfunction may contribute to SPCs by assessing SPCs associated with known immune responsive skin cancers, invasive and in situ squamous cell carcinoma (...) , Kaposi sarcoma, and Merkel cell carcinoma. Cancers were identified from the Swedish Cancer Registry from the year 1958 to 2015. Standardized relative risks were calculated bidirectionally for any SPC after skin cancer and for skin cancer as SPC. Over 80,000 first primary cancers were identified for each invasive and in situ squamous cell carcinoma of the skin. Bidirectional increased risks were observed for 26 cancers associated with invasive skin cancer; the Spearman rank correlation was 0.72 (P

2019 Journal of Investigative Dermatology

10. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) Full Text available with Trip Pro

, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S. Introduction Squamous cell carcinoma of the head and neck (HNSCC) is the 9th leading cancer by incidence worldwide and constitutes 90% of all head and neck cancers [ , ]. In the US, approximately 50,000 new cases of HNSCC and more than 10,000 deaths occur per year [ , , , ]. HNSCC is a biologically diverse and genomically heterogeneous disease that arises from the squamous mucosal lining of the upper aerodigestive (...) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) | Journal for ImmunoTherapy of Cancer | Full Text Advertisement Search Search all BMC articles Search The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment

2019 Society for Immunotherapy of Cancer

11. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

cutaneous squamous cell carcinoma (TA592) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 6 of 18and emotionally challenging and emotionally challenging 3.1 Cutaneous squamous cell carcinoma (CSCC) is a distinct disease that differs from both malignant melanoma and other squamous cell carcinomas such as primary head and neck or lung squamous cell carcinoma. Risk factors include exposure to ultraviolet radiation (...) is recommended for use within the Cancer Drugs Fund und 3.14 The committee recommended cemiplimab for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic CSCC in adults when curative surgery or curative radiotherapy is not appropriate, until disease progression or for up to 24 months (whichever is sooner). It is recommended Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592) © NICE 2019. All rights reserved. Subject to Notice

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Post-hysterectomy rare collision vulva tumor with long-term human papilloma virus infection composed of squamous cell carcinoma of the labia major and adenosquamous carcinoma of bartholin gland: A case report. Full Text available with Trip Pro

Post-hysterectomy rare collision vulva tumor with long-term human papilloma virus infection composed of squamous cell carcinoma of the labia major and adenosquamous carcinoma of bartholin gland: A case report. Post-hysterectomy collision tumors of the vulva has rarely been reported. Though long-term HPV infection may induce vulva tumor, but the relationship between HPV infection and collision vulva tumor is not clear. And there are no clear rules of the post-hysterectomy cancer surveillance (...) with long-term HPV infection composed of squamous cell carcinoma of the labia major and adenosquamous carcinoma of bartholin gland.The extensive excision of the vulva, bilateral inguinal lymph nodes dissection, and local skin flap transposition surgeon was done to this patient. The final certificate diagnosis was: vulvar tumor T1bM0N0 composed of squamous cell carcinoma of the labia major and adenosquamous carcinoma of bartholin gland; HPV infection; post hysterectomy, and bilateral salpingectomy.The

2019 Medicine

13. Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. Full Text available with Trip Pro

Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. Skin cancer patients are primarily at increased risk of developing subsequent skin cancers of the same type. Shared risk factors might also increase the occurrence of a different type of subsequent skin cancer.To investigate risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma (SCC) and basal (...) cell carcinoma (BCC).All melanoma and SCC patients included in the national Netherlands Cancer Registry (NCR) and all BCC patients included in the regional Eindhoven Cancer Registry (ECR) between 1989 and 2009 were followed until diagnosis of a subsequent different skin cancer (melanoma, SCC or BCC), date of death or end of study. Cumulative risks, standardized incidence ratios (SIR) and absolute excess risks (AER) of subsequent skin cancers were calculated.A total of 50 510 melanoma patients

2017 Journal of the European Academy of Dermatology and Venereology

14. Cemiplimab (Libtayo) - for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

guidelines for the management of the patient with primary cutaneous squamous cell carcinoma in 2002. 9 The guidance was subsequently updated in 2009 and is currently being reviewed. The European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) published Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus- based interdisciplinary guideline in 2015. 10 (...) A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European journal of cancer (Oxford, England : 1990). 2015;51(14):1989- 2007. Epub 2015/07/30. This assessment is based on data submitted by the applicant company up to and including 11 October 2019. *Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the SMC on guidelines

2020 Scottish Medicines Consortium

15. Cemiplimab (Libtayo) - cutaneous squamous cell carcinoma

and why it is authorised in the EU What is Libtayo and what is it used for? Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). It is used in patients who cannot have surgery or treatment with radiation to cure their disease. Libtayo contains the active substance cemiplimab. How is Libtayo used? Treatment (...) from attacking the cancer. By attaching to the receptor, cemiplimab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells. What benefits of Libtayo have been shown in studies? Libtayo is effective at treating cutaneous squamous cell carcinoma in many patients. In a main study involving a total of 193 patients, the cancer shrank in around 39% of patients with metastatic disease Libtayo (cemiplimab) EMA/357238/2019 Page 2/3

2019 European Medicines Agency - EPARs

16. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate Full Text available with Trip Pro

ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate Squamous cell carcinoma (SCC) is the second most common form of skin cancer and the mechanism(s) involved in the progression of this tumor are unknown. Increases in the expression of IL-33/ST2 axis components have been demonstrated to contribute to neoplastic transformation in several tumor models and interleukin-33 (...) is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Based on these observations, we sought to determine the role of the IL-33/ST2 pathway during the development of SCC. Our findings show that ST2-deficiency led to a marked decrease in the severity of skin lesions, suggesting that ST2 signaling contributed to tumor development. An analysis of tumor lesions in wild-type and ST2KO mice revealed that a lack of ST2 was associated with specific and significant reductions

2018 Oncotarget

17. Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24

Brockhaus ? Natalia Wolfram Keywords: xxx, xxx Keywords: nivolumab, carcinomasquamous cell, head and neck neoplasms, benefit assessment, NCT02105636 Addendum A17-54 Version 1.0 Nivolumab – Addendum to Commission A17-24 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 1 Background 1 2 Assessment 2 2.1 Assessment of the analyses on adverse events subsequently submitted 2 2.2 Assessment of the subgroup (...) Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24 1 Translation of addendum A17-54 Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs) – Addendum zum Auftrag A17-24 (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 October 2017 1.0 Commission: A17-54 Version: Status

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Tumor cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Full Text available with Trip Pro

Tumor cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Incidence of epidermal keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is increasing worldwide.To study the role of complement classical pathway components C1q, C1r and C1s in the progression of cSCC.The mRNA levels of C1Q subunits, C1R and C1S in cSCC cell lines, normal human epidermal keratinocytes (NHEKs), cSCC tumors in vivo and normal skin were analyzed with quantitative (...) skin. Abundant expression of C1r and C1s by tumor cells was detected in invasive sporadic cSCCs and recessive dystrophic epidermolysis bullosa-associated cSCCs, whereas the expression of C1r and C1s was lower in cSCC in situ, actinic keratosis, and normal skin. Knockdown of C1r and C1s expression in cSCC cells inhibited activation of ERK1/2 and Akt, promoted apoptosis of cSCC cells and significantly suppressed growth and vascularization of human cSCC xenograft tumors in vivo.These results provide

2019 British Journal of Dermatology

19. Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity Full Text available with Trip Pro

Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity We show that suppression of the spliceosome has potential for the treatment of cutaneous squamous cell carcinoma (cSCC). The small-molecule inhibitors of the spliceosome at the most advanced stage of development target the splicing factor SF3B1/SF3b155. The majority of cSCC cell lines are more sensitive than normal skin cells to death (...) for a key role of the p53 pathway in the response to spliceosome disruption. SF3B1 inhibition causes wild-type p53 upregulation associated with altered mRNA splicing and reduced protein expression of both principal p53 negative regulators MDMX/MDM4 and MDM2. We observed that wild-type p53 can promote pladienolide B-induced death in tumour cells. However, p53 is commonly inactivated by mutation in cSCCs and p53 participates in killing normal skin cells at high concentrations of pladienolide B. This may

2018 Oncotarget

20. ASTRO Guideline on Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin

(-) N3a Metastasis in a lymph node >6 cm in greatest dimension and ENE (-) N3b Clinically overt ENE (+) M category T4a Tumor with gross cortical bone/marrow invasion M0 No distant metastases M1 Metastasis to =1 distant organ T4b Tumor with skull base invasion and/or skull base foramen involvement Abbreviations: AJCC = American Joint Committee on Cancer; and ENE = extranodal extension. * Applies only to cutaneous squamous cell carcinomas and all other nonmelanoma skin carcinomas of the head and neck (...) . Many important clinical questions addressed in guidelines do not lend themselves to clinical trials but there still may be consensus that the benefits of a treatment or diagnostic test clearly outweigh its risks and burden. 6 ASTRO Radiation for Basal and Squamous Cell Cancers Guideline Practical Radiation Oncology 1. Introduction Skin cancer is the most prevalent cancer type in the United States with an incidence rate of over 5 million cases annually. 1 Basal cell carcinoma (BCC) and cutaneous

2020 American Society for Radiation Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>